DK1911442T3 - Præparat til forebyggelse og/eller behandling af vaskulære lidelser - Google Patents

Præparat til forebyggelse og/eller behandling af vaskulære lidelser

Info

Publication number
DK1911442T3
DK1911442T3 DK07120681T DK07120681T DK1911442T3 DK 1911442 T3 DK1911442 T3 DK 1911442T3 DK 07120681 T DK07120681 T DK 07120681T DK 07120681 T DK07120681 T DK 07120681T DK 1911442 T3 DK1911442 T3 DK 1911442T3
Authority
DK
Denmark
Prior art keywords
fraction
prevention
treatment
vascular disorders
preparation
Prior art date
Application number
DK07120681T
Other languages
Danish (da)
English (en)
Inventor
Amanda Johanne Kiliaan
Robert Johan Joseph Hageman
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27074171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1911442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Application granted granted Critical
Publication of DK1911442T3 publication Critical patent/DK1911442T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
DK07120681T 2000-05-08 2001-05-08 Præparat til forebyggelse og/eller behandling af vaskulære lidelser DK1911442T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56638600A 2000-05-08 2000-05-08
US09/703,798 US7226916B1 (en) 2000-05-08 2000-11-02 Preparation for the prevention and/or treatment of vascular disorders
PCT/NL2001/000347 WO2001084961A2 (en) 2000-05-08 2001-05-08 Preparation for the prevention and/or treatment of vascular disorders

Publications (1)

Publication Number Publication Date
DK1911442T3 true DK1911442T3 (da) 2009-06-08

Family

ID=27074171

Family Applications (3)

Application Number Title Priority Date Filing Date
DK01928256T DK1282365T3 (da) 2000-05-08 2001-05-08 Præparat til forebyggelse og/eller behandling af vaskulære lidelser
DK07120681T DK1911442T3 (da) 2000-05-08 2001-05-08 Præparat til forebyggelse og/eller behandling af vaskulære lidelser
DK09156648.9T DK2070519T6 (en) 2000-05-08 2001-05-08 Preparation for the prevention and / or treatment of dementia syndromes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01928256T DK1282365T3 (da) 2000-05-08 2001-05-08 Præparat til forebyggelse og/eller behandling af vaskulære lidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09156648.9T DK2070519T6 (en) 2000-05-08 2001-05-08 Preparation for the prevention and / or treatment of dementia syndromes

Country Status (13)

Country Link
US (5) US7226916B1 (de)
EP (5) EP1282365B1 (de)
CN (1) CN1245984C (de)
AT (2) ATE431133T1 (de)
AU (1) AU2001255114A1 (de)
CA (1) CA2408032C (de)
CY (3) CY1107237T1 (de)
DE (2) DE60132081T2 (de)
DK (3) DK1282365T3 (de)
ES (3) ES2533362T7 (de)
HK (1) HK1052439B (de)
PT (3) PT1282365E (de)
WO (1) WO2001084961A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951842T3 (da) * 1999-01-20 2003-01-06 Nutricia Nv Ernæringsprodukt til et spædbarn
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2003013549A2 (de) * 2001-08-09 2003-02-20 Degussa Food Ingredients Gmbh Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
DE10217557A1 (de) * 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
DE10217555A1 (de) * 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
DE10250727B4 (de) * 2002-04-19 2008-07-10 Cargill, Incorporated, Wayzata Matrix mit einer bioaktiven Phospholipid-haltigen Komponente
WO2003088949A2 (de) * 2002-04-19 2003-10-30 Bioghurt Biogarde Gmbh & Co. Kg. Matrix mit einer bioaktiven phospholipid-haltigen komponente
EP1501493B1 (de) * 2002-05-03 2009-10-07 Pronova BioPharma Norge AS Verwendung von epa and dha zur sekundären prevention von schlaganfällen
CN100469361C (zh) 2002-06-19 2009-03-18 纽迪希亚公司 治疗或预防哺乳动物遭受代谢作用压力时的分解代谢或刺激性合成代谢的方法及组合物
EP1388295A1 (de) * 2002-08-07 2004-02-11 Nestec S.A. DHA-enthaltendes Nahrungsmittel auf Getreidebasis
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
ES2283979T3 (es) * 2003-02-05 2007-11-01 N.V. Nutricia Composicion enteral para la prevencion y/o tratamiento de sepsis.
MXPA05010930A (es) * 2003-04-17 2005-11-25 Boehringer Ingelheim Int Suplemento multivitaminico y mineral para mujeres embarazadas.
US8703209B2 (en) 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
WO2004112777A1 (ja) * 2003-06-20 2004-12-29 Mochida Pharmaceutical Co., Ltd. 下肢静脈瘤予防・治療用組成物
EP1643863A2 (de) * 2003-07-10 2006-04-12 Carl A. Forest Nahrungsmittel, getränke, würzmittel, gewürze und salatsaucen mit spezialzusätzen
US8017160B2 (en) * 2003-08-15 2011-09-13 Russell Jaffe Enhancement of magnesium uptake in mammals
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
IL158139A0 (en) * 2003-09-25 2004-09-27 Enzymotec Ltd Stabilized formulations of phosphatidyl serine
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
EP1645276A1 (de) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Behandlung von neurodegenerativen Erkrankungen
JP5503846B2 (ja) * 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用
EP3090740A1 (de) 2005-05-23 2016-11-09 Massachusetts Institute of Technology Zusammensetzungen enthaltend eicosapentaensäure zur verbesserung des kognitiven funktion
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
EP1951071A2 (de) * 2005-10-18 2008-08-06 Artmed S.r.l. Nutrazeutika- und pharmazeutikazusammensetzungen, die cholin als adjuvans enthalten, für die vorbeugung und behandlung von retinopathien und glaukom
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US8871808B2 (en) 2006-06-22 2014-10-28 Ben-Gurion University Of The Negev Research And Development Authority Et Al. Over-production of dihomo linolenic acid by a mutant strain of Parietochloris incisa
ES2790590T3 (es) * 2006-07-14 2020-10-28 Kaydence Pharma As Productos farmacéuticos y nutricéuticos que comprenden vitamina K2
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
EP2689782B1 (de) 2007-06-26 2020-05-13 N.V. Nutricia Verbesserung des Gedächtnisses von Personen mit einem Mini-Mental Status Test von 24-26
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
ES2402076T3 (es) * 2007-08-13 2013-04-26 Ben-Gurion University Of The Negev Research And Development Authority Sobreproducción de ácido dihomo-gamma linolénico por una cepa mutante de Parietochloris incisa
DE102007042557A1 (de) * 2007-09-07 2009-03-19 Membramed Gmbh Neuartige Formulierung von Phospholipiden
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009070589A1 (en) * 2007-11-30 2009-06-04 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
PL2609812T3 (pl) 2007-12-20 2019-02-28 N.V. Nutricia Ciekły produkt zawierający nukleotydy/nukleozydy
US9034399B2 (en) * 2008-01-03 2015-05-19 Melaleuca, Inc. Dietary compositions for promoting brain health
US20110052556A1 (en) 2008-02-29 2011-03-03 Biolab Sanus Farmaceutical Ltda Pharmaceutical composition comprising racetam and carnitine and process for its preparation
EP2172203A1 (de) * 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmazeutisches Zusammensetzung zur Behandlung von Magen-Darm-Reizungsstörungen
CA2777233A1 (en) * 2008-10-13 2010-04-22 Pregnant Princess & Co. Ltd. Compositions and methods for treating varicose veins
PL2429317T5 (pl) * 2009-04-17 2019-09-30 Natac Pharma, S.L. Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego
US8623274B2 (en) 2009-11-25 2014-01-07 Loma Linda University Medical Center Chitosan-based hemostatic textile
EP2627326A2 (de) * 2010-10-12 2013-08-21 Vifor SA Neue omega-3- und omega-6 fettsäurzusammensetzungen und ihre verwendung
EP2732027B1 (de) 2011-07-12 2017-03-01 Foodchek Systems, Inc. Kulturmedium, verfahren zur kultivierung von salmonella und e. coli sowie verfahren zur erkennung von salmonella und e. coli
RU2505290C2 (ru) * 2011-10-31 2014-01-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтическая композиция, обладающая свойством снижения эндотелиальной дисфункции при заболеваниях сердечно-сосудистой системы
WO2013138368A1 (en) * 2012-03-12 2013-09-19 Loma Linda University Medical Center Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
CN103432156A (zh) * 2013-08-30 2013-12-11 深圳奥萨医药有限公司 ω-3脂肪酸和B族维生素的药物组合物及其用途
GB201405033D0 (en) 2014-03-20 2014-05-07 Isis Innovation Combination therapy
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
DE202014102551U1 (de) * 2014-05-30 2015-02-26 Orthomol Pharmazeutische Vertriebs Gmbh Diätetische Zubereitung in Form eines Riegels
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
DK3328214T3 (da) * 2015-07-29 2020-04-27 Abbott Lab Ernæringsprodukter med forbedret lipofil opløselighed og biotilgængelighed i en let blandbar form
CN105079009B (zh) * 2015-08-25 2018-05-01 厦门金达威生物科技有限公司 预防和/或治疗心脑血管疾病的组合物
CN107252089A (zh) * 2017-04-05 2017-10-17 吉林省润生特膳食品科技开发有限公司 一种山楂桃仁山药粉及其制备方法
JP6650650B2 (ja) 2017-12-21 2020-02-19 国立大学法人大阪大学 神経系疾患治療剤
CN110404049A (zh) * 2019-07-23 2019-11-05 张明 通过雾化吸入防治心脑血管病和老年痴呆的组合物及应用
FR3099339B1 (fr) * 2019-08-01 2022-06-17 Specialites Pet Food Hydrolysat protéique issu de poissons bleus
CN112843072A (zh) * 2021-01-12 2021-05-28 山东省科学院生物研究所 磷脂在调控血管生成方面的应用
CN113456640A (zh) * 2021-08-26 2021-10-01 烟台大学 石杉碱甲在心肌缺血损伤预防中的应用
AU2022345465A1 (en) 2021-09-17 2024-03-21 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
IT202200010583A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”
GB202209414D0 (en) * 2022-06-27 2022-08-10 Aker Biomarine Antarctic As Uses for phospholipid compositions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2824362A1 (de) 1978-06-01 1979-12-13 Josef Dipl Chem Dr Rer N Klosa Pharmazeutisches praeparat mit l-tryptophan
IT1212900B (it) * 1983-11-17 1989-11-30 Valle Francesco Della Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
NO862999L (no) 1985-07-26 1987-01-27 Yeda Res & Dev Lipidblanding for membranfluidisering.
US4897380A (en) 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPS63208524A (ja) 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
IL86423A0 (en) 1987-05-19 1988-11-15 Baylor College Medicine Pharmaceutical compositions for the treatment of alzheimer's disease
EP0342211B1 (de) 1987-09-30 1994-03-30 FREGLY, Melvin J. Behandlung von arteriosklerosis durch verabreichung von l-tryptophane oder l-5-hydroxytryptophan
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US5004615A (en) * 1988-04-27 1991-04-02 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
JP2732109B2 (ja) * 1989-02-10 1998-03-25 正樹 今川 痴呆治療剤
JP2909508B2 (ja) * 1989-02-14 1999-06-23 マルハ株式会社 オキアミリン脂質の分取方法
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH02302732A (ja) 1989-05-18 1990-12-14 Seiko Epson Corp 液晶表示装置
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5077069A (en) 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
US5108767A (en) 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
DE4309217A1 (de) * 1992-01-18 1994-07-28 Margarethe Rabien Kombinationspräparat Pantothensäure bzw. Dexpanthen + alpha-Liponesäure + Vitamin E (Muskeldystrophie, Polyneuropathie, Muskelatrophie Atoxie, neue Indikation (alpha-Liponsäure + Pantothensäure) Alzheimersche Krankheit
US5234702A (en) 1992-03-19 1993-08-10 Abbott Laboratories Antioxidant system for powdered nutritional products
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
JPH0717855A (ja) 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
DE4304394A1 (en) 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
EP0700303A4 (de) 1993-05-28 1996-08-21 Abbott Lab Enterales ernägrungsprodukt
AU1265295A (en) * 1993-12-10 1995-06-27 Sami A. Hashim Reducing likelihood of vascular disorders in susceptible patients
FR2714574B1 (fr) 1993-12-31 1996-03-15 Inst Rech Biolog Sa Nouveaux suppléments alimentaires pour la nutrition des très jeunes enfants.
JPH07224142A (ja) 1994-02-08 1995-08-22 Dai Ichi Kogyo Seiyaku Co Ltd エポキシ樹脂及びエポキシ樹脂組成物
EP0754001B1 (de) 1994-04-01 2002-01-23 Abbott Laboratories Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben
CA2150741A1 (en) 1994-06-17 1995-12-18 Susan Trimbo Pediatric lipid emulsion
JP3053537B2 (ja) 1994-11-08 2000-06-19 株式会社ヤクルト本社 脳機能改善剤
GB9423625D0 (en) * 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5589468A (en) 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
EP0726073A3 (de) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten
JPH08252856A (ja) 1995-03-16 1996-10-01 Asahi Glass Co Ltd 樹脂枠体付き窓用板状体の製造装置
JPH0954212A (ja) * 1995-08-11 1997-02-25 Sharp Corp 位相差フィルム及びその製造方法、並びに液晶表示素子
JP3791951B2 (ja) 1995-11-08 2006-06-28 株式会社ヤクルト本社 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
GB9606736D0 (en) * 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
WO1997037670A1 (en) 1996-04-10 1997-10-16 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JP3664814B2 (ja) * 1996-06-26 2005-06-29 旭化成ケミカルズ株式会社 血中脂質改善剤及び食品添加剤
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
JPH10140919A (ja) 1996-11-11 1998-05-26 Mika Oosawa 建物空間内の間仕切り構造
EP0843972B1 (de) 1996-11-20 2002-07-31 N.V. Nutricia Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
JPH10165119A (ja) * 1996-12-10 1998-06-23 Seijiro Yanai イチョウ葉エキス添加強化米及びその製造方法
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
GB9701675D0 (en) 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
JP2001511153A (ja) 1997-02-04 2001-08-07 ブイ. コスバブ,ジョン 血管変性性疾患の予防および処置のための組成物および方法
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US5820867A (en) 1997-04-24 1998-10-13 Bewicke; Calverly M. General anti-depressant composition for dietary supplement
AU7222598A (en) 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0891719A1 (de) 1997-07-14 1999-01-20 N.V. Nutricia Narungszusammensetzungen mit Gehalt an Methionin
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
AU8925998A (en) 1997-09-03 1999-03-22 Macro Hi-Tech Jv, Ltd. Huperzine a derivatives
JP2001521002A (ja) 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク. 脳の代謝機能不全のための栄養補充剤
US5922704A (en) * 1997-12-24 1999-07-13 Feeling Fine Company Llc Optimal nutritional supplement for men
FR2773484B1 (fr) * 1998-01-09 2001-03-30 Pierre Moreau Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
CA2317671A1 (en) 1998-01-13 1999-07-22 Rexall Sundown, Inc. St. john's wort and methyl donor composition and uses thereof
WO1999037155A1 (en) 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
GB9808579D0 (en) 1998-04-22 1998-06-24 Novartis Nutrition Ag Improvements in or relating to organic compounds
CA2330811A1 (en) 1998-05-04 1999-11-11 Andreas Johannes Kesel Monomeric, oligomeric and polymeric knoevenagel condensation products
CN1235770A (zh) * 1998-05-15 1999-11-24 武汉华凯保健品开发有限公司 银杏茶
WO1999064028A1 (en) 1998-06-11 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Protecting neurons from ischemia
IT1299195B1 (it) 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
JP2000148134A (ja) 1998-11-13 2000-05-26 Seiko Epson Corp 画像表示方法および画像処理装置
FR2788437B1 (fr) 1999-01-14 2006-08-11 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
US6120814A (en) 1999-02-22 2000-09-19 Nature's One, Inc. Organic nutritional formula
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8801693B2 (en) 2010-10-29 2014-08-12 C. R. Bard, Inc. Bioimpedance-assisted placement of a medical device

Also Published As

Publication number Publication date
HK1052439B (zh) 2008-02-29
DK1282365T3 (da) 2008-03-31
US20130157978A1 (en) 2013-06-20
PT1911442E (pt) 2009-09-01
US20080193561A1 (en) 2008-08-14
DE60132081D1 (de) 2008-02-07
CY1109248T1 (el) 2014-07-02
US20100303784A1 (en) 2010-12-02
ATE381894T1 (de) 2008-01-15
US20070202194A1 (en) 2007-08-30
WO2001084961A2 (en) 2001-11-15
EP1282365B1 (de) 2007-12-26
DK2070519T6 (en) 2018-11-19
EP1911442A2 (de) 2008-04-16
US8865687B2 (en) 2014-10-21
WO2001084961A3 (en) 2002-08-15
EP2070519B3 (de) 2018-08-22
US7560447B2 (en) 2009-07-14
CN1245984C (zh) 2006-03-22
PT2070519E (pt) 2015-03-26
AU2001255114A1 (en) 2001-11-20
EP2070519B1 (de) 2014-12-24
CN1440240A (zh) 2003-09-03
EP2316426B1 (de) 2016-11-30
EP1282365A2 (de) 2003-02-12
EP2070519A1 (de) 2009-06-17
ES2298232T3 (es) 2008-05-16
DE60138742D1 (de) 2009-06-25
EP1911442A3 (de) 2008-05-21
CY1107237T1 (el) 2012-11-21
US7772217B2 (en) 2010-08-10
ES2533362T7 (es) 2019-02-04
US7226916B1 (en) 2007-06-05
CA2408032C (en) 2012-08-21
EP2292210A1 (de) 2011-03-09
CA2408032A1 (en) 2001-11-15
US8377912B2 (en) 2013-02-19
HK1052439A1 (en) 2003-09-19
EP1911442B1 (de) 2009-05-13
CY1116212T1 (el) 2017-02-08
ES2326928T3 (es) 2009-10-21
EP2316426A1 (de) 2011-05-04
DE60132081T2 (de) 2008-12-18
DK2070519T3 (da) 2015-03-30
ATE431133T1 (de) 2009-05-15
ES2533362T3 (es) 2015-04-09
PT1282365E (pt) 2008-03-24

Similar Documents

Publication Publication Date Title
DK1911442T3 (da) Præparat til forebyggelse og/eller behandling af vaskulære lidelser
DK1275399T3 (da) Fremgangsmåde og præparat til forebyggelse og/eller behandling af vaskulære lidelser og sekundære lidelser der er associeret dermed
EP2340824A3 (de) Verfahren und Zubereitung zur Verringerung der Schwere von ADHD und/oder motorischen Störungen
ECSP045154A (es) Composiciones de fórmula para infantes que comrende cantidades aumentadas de alfa - lactalbumin
BRPI0813320A2 (pt) Fração lipídica, e, produto farmacêutico ou nutricional
WO2002043659A3 (en) Composition containing statins and calcium for improved cardiovascular health
WO2008005869A3 (en) Infant formulas for early brain development
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
DK1082298T3 (da) 1-alfa-hydroxy-25-en-vitamin D, analoger og anvendelser deraf
DK1411960T3 (da) Födevareprodukt af beriget risklid til fremme af hjerte-kar-sundhed
WO2005013947A3 (en) Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
WO2003068231A3 (de) Mittel, enthaltend folsäure, vitamin b6 und vitamin b12, und dessen verwendung
DE602004019884D1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
WO2000064276A3 (en) Enriched spreads
DK1638417T3 (en) COMBINATIONS OF VASO PROTECTIVE AGENTS AND FORMS CONTAINING THESE
EP1325747A3 (de) Diätergänzung für neuropatischen Patienten
WO2017069632A1 (en) Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017069631A1 (en) Method for improving equilibrioception in healthy individuals and nutritional composition
ITRM20010030A0 (it) Sali di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per la loro pr
AR044739A1 (es) Composiciones lacteas y metodos para su preparacion
TH96559A (th) องค์ประกอบโภชนาการสำหรับทารกสำหรับการป้องกันโรคอ้วน
TH96559B (th) องค์ประกอบโภชนาการสำหรับทารกสำหรับการป้องกันโรคอ้วน